Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia

D. K. Tack, L. Letendre, P. S. Kamath, A. Tefferi

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed.

Original languageEnglish (US)
Pages (from-to)895-897
Number of pages3
JournalBone Marrow Transplantation
Volume28
Issue number9
DOIs
StatePublished - 2001

Keywords

  • Acute myeloid leukemia
  • Hepatotoxicity
  • Mylotarg

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this